Abstract: Embodiments of the present disclosure provide a method for treating cellular inflammation induced by AFB1, comprising administering to a patient an agent that increases a content or an expression level of miR-9, wherein the agent that increases the content or the expression level of miR-9 is miR-9 mimics or an expression vector containing miR-9, a nucleotide sequence of the miR-9 mimics is shown in SEQ ID No. 5 and a SEQ ID No. 6, and a nucleotide sequence of the miR-9 is shown in SEQ ID No. 5. The present disclosure increases the content or the expression level of miR-9 to antagonize an upstream signaling, block an occurrence of inflammatory response, and inhibit a pro-inflammatory effect of AFB1 on glomerular podocyte.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are methods for treatment of estrogen-related medical disorders. The methods of treatment may comprise administering to a subject in need of such treatment a composition comprising a therapeutically effective amount of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof.